Connect your AI

Kymera Therapeutics KYMR Earnings yield

Earnings yield at other companies

PfizerPFE

6.8%—

Johnson & JohnsonJNJ

3.6%-1.9pp

Regeneron PharmaceuticalsREGN

5.4%-1.1pp

ImmunityBio, Inc.IBRX

-10.8%-2.6pp

Krystal Biotech, Inc.KRYS

3%+0.6pp

Protagonist TherapeuticsPTGX

-1.7%-3.6pp

Other financials

Income statement

Revenue$34.4M+55.5%

Operating income-$84.2M-13.1%

Net income-$69.2M-5.6%

EPS (diluted)-$0.71+13.4%

Balance sheet

Cash & equivalents$144.1M+60.2%

Total debt$82.2M-6.5%

Total equity$1.5B+95.8%

Total assets$1.7B+81.7%

Cash flow

Operating cash flow-$88.8M-12.2%

CapEx$434.0K-7.1%

Free cash flow-$89.3M-12.1%

Valuation

Market cap$7.44B+283%

Enterprise value$7.38B+280%

P/S144.5×+111×

Profitability

Operating margin-697.7%+635pp

Net margin-612%+602pp

FCF margin-474%+92.4pp

Returns & leverage

Return on equity-27.1%-3.7pp

Debt / equity0.1×-0.1×

Current ratio10.8×+2.3×

Where this comes from

Calculated from Kymera Therapeutics’s reported figures.

net income/market cap=-4.6%

Based on trailing twelve months.

The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kymera Therapeutics's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Kymera Therapeutics's earnings yield?: Kymera Therapeutics (KYMR) reported earnings yield of -4.6% in Q1 2026.
How has Kymera Therapeutics's earnings yield changed year-over-year?: Kymera Therapeutics's earnings yield increased by 65.8% year-over-year, from -13.6% to -4.6%.
What is the long-term trend for Kymera Therapeutics's earnings yield?: Over 5 years (2020 to 2025), Kymera Therapeutics's earnings yield has grown at a 24.9% compound annual growth rate (CAGR), from -1.6% to -5%.
What does earnings yield mean?: Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.